April's good start, the innovative drug concept collectively explodes, Ruizhi Medicine hits the 20cm daily limit

Ask AI · How will the AACR Annual Meeting lead new trends in global cancer treatment?

On April 1st, the three major A-shares indices all rose by more than 1%, with the STAR Market 50 Index up over 3%. In terms of sectors, innovative drug concepts celebrated collectively, with Guangsheng Tang, Ruizhi Medicine, and Aidi Pharmaceuticals all hitting the 20% daily limit, Tianjin Pharmaceutical four consecutive limit-ups, and multiple concept stocks like Huiyu Pharmaceutical, Yifang Biotech, and Chengda Pharmaceuticals showing leading gains.

In terms of news, the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting has become the catalyst igniting enthusiasm in the sector. This year’s AACR Annual Meeting will be held from April 17 to 22 in San Diego, California. As one of the largest and most influential academic events in the global oncology field, the AACR Annual Meeting is an important barometer for the development of the global innovative drug industry. The conference annually gathers top scientists, clinicians, and industry leaders worldwide, focusing on showcasing the most cutting-edge breakthrough research in cancer treatment.

Huayuan Securities’ research report believes that China’s pharmaceutical industry has completed the shift from imitation to innovation, with innovative drugs becoming the new engine for industry growth. Investment in 2026 should focus on the dual main lines of “technology innovation-led” and “performance and valuation recovery,” paying special attention to leading innovative drug companies with global competitiveness and strong overseas expansion capabilities, while actively deploying frontier technologies such as AI healthcare and brain-computer interfaces.

(Disclaimer: The content of this article is for reference only and does not constitute investment advice. Investors operate at their own risk.)